JP2013525337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525337A5 JP2013525337A5 JP2013505533A JP2013505533A JP2013525337A5 JP 2013525337 A5 JP2013525337 A5 JP 2013525337A5 JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013525337 A5 JP2013525337 A5 JP 2013525337A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- sodium
- surfactant
- polyoxyethylene
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 19
- -1 brij Chemical compound 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 9
- 239000004094 surface-active agent Substances 0.000 claims 9
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 6
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 6
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 6
- 229960003804 efavirenz Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000002002 slurry Substances 0.000 claims 5
- 229920002675 Polyoxyl Polymers 0.000 claims 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims 2
- FOUZISDNESEYLX-UHFFFAOYSA-N N-hydroxyethyl glycine Natural products OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Chemical class 0.000 claims 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 150000001298 alcohols Polymers 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- 239000002280 amphoteric surfactant Substances 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 239000003833 bile salt Substances 0.000 claims 2
- 229940093761 bile salts Drugs 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 2
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 150000002334 glycols Chemical class 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229920000847 nonoxynol Polymers 0.000 claims 2
- 229920002113 octoxynol Polymers 0.000 claims 2
- 229940066429 octoxynol Drugs 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- 239000003208 petroleum Substances 0.000 claims 2
- 229920000058 polyacrylate Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Chemical class 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 239000007970 homogeneous dispersion Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1296/MUM/2010 | 2010-04-20 | ||
| IN1296MU2010 | 2010-04-20 | ||
| PCT/GB2011/000620 WO2011131943A2 (en) | 2010-04-20 | 2011-04-20 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525337A JP2013525337A (ja) | 2013-06-20 |
| JP2013525337A5 true JP2013525337A5 (enExample) | 2014-06-05 |
Family
ID=44625957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505533A Pending JP2013525337A (ja) | 2010-04-20 | 2011-04-20 | 医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130302415A1 (enExample) |
| EP (1) | EP2560617A2 (enExample) |
| JP (1) | JP2013525337A (enExample) |
| KR (1) | KR20130076818A (enExample) |
| CN (1) | CN102985072A (enExample) |
| AU (1) | AU2011244783B2 (enExample) |
| BR (1) | BR112012026843A2 (enExample) |
| CA (1) | CA2796494A1 (enExample) |
| GT (1) | GT201200284A (enExample) |
| NZ (1) | NZ602955A (enExample) |
| RU (1) | RU2012149115A (enExample) |
| WO (1) | WO2011131943A2 (enExample) |
| ZA (1) | ZA201207670B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115633D0 (en) * | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| US10646452B2 (en) * | 2013-03-15 | 2020-05-12 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| IN2013MU03370A (enExample) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| WO2015140569A1 (en) * | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
| CN104224790A (zh) * | 2014-09-28 | 2014-12-24 | 苏州普罗达生物科技有限公司 | 一种依法韦仑组合物及其制备方法 |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| WO2019023392A1 (en) | 2017-07-25 | 2019-01-31 | Elektrofi, Inc. | FORMATION OF PARTICLES COMPRISING AGENTS |
| US20230040901A1 (en) * | 2018-01-04 | 2023-02-09 | PlantTec Medical GmbH | Pharmaceutical composition for inhibiting postoperative adhesions |
| ES2732498B2 (es) * | 2018-05-21 | 2020-04-27 | Consejo Superior Investigacion | Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico. |
| WO2019226969A1 (en) | 2018-05-24 | 2019-11-28 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| CN112236141A (zh) * | 2018-06-11 | 2021-01-15 | 大塚制药株式会社 | 包含德拉马尼的组合物 |
| AU2020214626B2 (en) | 2019-01-31 | 2025-10-16 | Halozyme Hypercon, Inc. | Particle formation and morphology |
| AU2020344675B2 (en) | 2019-09-13 | 2026-06-25 | Halozyme Hypercon, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| KR20220109430A (ko) | 2019-12-02 | 2022-08-04 | 아스트라제네카 아베 | 6-(2-클로로-6-메틸피리딘-4-일)-5-(4-플루오로페닐)-1,2,4-트리아진-3-아민의 고체 약학 제형 |
| US12377050B2 (en) | 2020-04-17 | 2025-08-05 | Elektrofi, Inc. | Methods of forming particles by continuous droplet formation and dehydration |
| WO2021216475A1 (en) * | 2020-04-20 | 2021-10-28 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
| CN112245400B (zh) * | 2020-11-10 | 2023-01-20 | 蓝龙药业(北京)有限公司 | 一种依法韦仑微片剂、制备方法及其应用 |
| CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| PE20000559A1 (es) | 1998-05-27 | 2000-07-05 | Merck & Co Inc | Formulacion de tabletas comprimidas de efavirenz |
| AU2002359518A1 (en) * | 2001-11-27 | 2003-06-10 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| US20070003623A1 (en) * | 2005-06-29 | 2007-01-04 | Wyeth | Formulations of conjugated estrogens and bazedoxifene |
| US20080026062A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
| TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | 活效製藥股份有限公司 | 微粉碎化有機化合物粒子之製法 |
| CA2697150A1 (en) * | 2007-08-17 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| JP4606444B2 (ja) * | 2007-08-21 | 2011-01-05 | アピ株式会社 | アントシアニン含有経口投与用組成物及びその製造方法 |
| WO2010068899A1 (en) * | 2008-12-12 | 2010-06-17 | Creighton University | Nanoparticles comprising combinations of antiretroviral agents and use thereof |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
-
2011
- 2011-04-20 BR BR112012026843A patent/BR112012026843A2/pt not_active IP Right Cessation
- 2011-04-20 NZ NZ602955A patent/NZ602955A/en not_active IP Right Cessation
- 2011-04-20 AU AU2011244783A patent/AU2011244783B2/en not_active Ceased
- 2011-04-20 EP EP11716002A patent/EP2560617A2/en not_active Withdrawn
- 2011-04-20 CN CN2011800201397A patent/CN102985072A/zh active Pending
- 2011-04-20 WO PCT/GB2011/000620 patent/WO2011131943A2/en not_active Ceased
- 2011-04-20 JP JP2013505533A patent/JP2013525337A/ja active Pending
- 2011-04-20 CA CA2796494A patent/CA2796494A1/en not_active Abandoned
- 2011-04-20 RU RU2012149115/15A patent/RU2012149115A/ru not_active Application Discontinuation
- 2011-04-20 KR KR1020127030186A patent/KR20130076818A/ko not_active Ceased
-
2012
- 2012-10-12 ZA ZA2012/07670A patent/ZA201207670B/en unknown
- 2012-10-18 GT GT201200284A patent/GT201200284A/es unknown
-
2013
- 2013-07-14 US US13/941,525 patent/US20130302415A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537182A5 (enExample) | ||
| RU2012149115A (ru) | Фармацевтическая композиция | |
| JP2013538845A5 (enExample) | ||
| RU2013113752A (ru) | Фармацевтическая композиция | |
| WO2013132457A3 (en) | Nanocrystalline solid dispersion compositions and process of preparation thereof | |
| JP2010047579A5 (enExample) | ||
| CN104288154A (zh) | 一种含有不同粒径范围的法匹拉韦药物组合物 | |
| AU2018253545A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| JP2014510704A5 (enExample) | ||
| WO2012051426A3 (en) | Aggregate nanoparticulate medicament formulations, manufacture and use thereof | |
| AR093449A1 (es) | Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo | |
| MX337827B (es) | Novedosos derivados polisacaridos y formas de administracion. | |
| AR063983A1 (es) | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada | |
| MY159172A (en) | Inhalable particles comprising tiotropium | |
| HRP20120583T1 (hr) | Oblici flupentiksola | |
| CN105982870A (zh) | 一种阿哌沙班片剂 | |
| WO2012053785A3 (ko) | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 | |
| CN104887633B (zh) | 一种利伐沙班片剂及其制备方法 | |
| IN2015DN01738A (enExample) | ||
| CN102406939A (zh) | 提高难溶性药物溶解性能以提高生物利用度的方法 | |
| CN203124062U (zh) | 一种具有三维空间分布喷嘴群的气流磨 | |
| CN104586814B (zh) | 一种阿瑞匹坦胶囊 | |
| CN103127016B (zh) | 富马酸比索洛尔片剂组合物及其制备方法 | |
| MX2012013178A (es) | Composicion antiparasitaria de amplio espectro de nitazoxanida, probioticos y prebioticos. | |
| CN111888477B (zh) | 一种贝达喹啉药物制剂 |